46.13
Soleno Therapeutics Inc stock is traded at $46.13, with a volume of 327.71K.
It is down -2.72% in the last 24 hours and down -6.18% over the past month.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
See More
Previous Close:
$47.42
Open:
$48.03
24h Volume:
327.71K
Relative Volume:
0.60
Market Cap:
$1.99B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-15.39
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-6.18%
1M Performance:
-6.18%
6M Performance:
-11.07%
1Y Performance:
-5.10%
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SLNO
Soleno Therapeutics Inc
|
46.13 | 1.99B | 0 | -38.99M | -24.94M | -2.9966 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
Dec-02-24 | Reiterated | Stifel | Buy |
Sep-03-24 | Initiated | H.C. Wainwright | Buy |
May-10-24 | Initiated | Robert W. Baird | Outperform |
Feb-05-24 | Initiated | Piper Sandler | Overweight |
Jan-23-24 | Initiated | Stifel | Buy |
Nov-21-23 | Resumed | Guggenheim | Buy |
Sep-29-20 | Initiated | Guggenheim | Buy |
Jan-10-20 | Initiated | Craig Hallum | Buy |
Dec-23-19 | Initiated | Oppenheimer | Outperform |
Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Allspring Global Investments Holdings LLC Sells 13,396 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
TimesSquare Capital Management LLC Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock Holdings Lowered by Allspring Global Investments Holdings LLC - MarketBeat
(SLNO) Long Term Investment Analysis - Stock Traders Daily
Soleno Therapeutics (NASDAQ:SLNO) Stock Passes Above Fifty Day Moving Average – Should You Sell? - Defense World
Soleno Therapeutics (NASDAQ:SLNO) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Price Target at $71.20 - Defense World
What is Lifesci Capital's Estimate for SLNO Q4 Earnings? - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Lifesci Capital to Strong-Buy Rating - MarketBeat
Trend Tracker for (SLNO) - Stock Traders Daily
Equities Analysts Set Expectations for SLNO Q4 Earnings - Defense World
SLNO Stock Sees Surge of Approximately 3.38% in Last Five Days - Knox Daily
What was Soleno Therapeutics Inc (SLNO)’s performance in the last session? - US Post News
Lifesci Capital Upgrades Soleno Therapeutics (NASDAQ:SLNO) to “Strong-Buy” - Defense World
BlackRock, Inc. Reduces Stake in Soleno Therapeutics Inc - GuruFocus.com
Moody Aldrich Partners LLC Purchases New Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Soleno Therapeutics, Inc. to Participate in February Investor Conferences - Nasdaq
Rare Disease Pioneer Soleno Takes Center Stage at Major Healthcare Investment Forums - StockTitan
(SLNO) Investment Report - Stock Traders Daily
Soleno Therapeutics executives receive pay raises and bonuses - MSN
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
Soleno Therapeutics executives receive pay raises and bonuses By Investing.com - Investing.com Nigeria
Soleno Therapeutics Enhances Executive Compensation Structure - TipRanks
Brokers Set Expectations for SLNO FY2025 Earnings - Defense World
Equities Analysts Issue Forecasts for SLNO FY2025 Earnings - MarketBeat
High Growth Tech Stocks to Watch in January 2025 - Simply Wall St
Soleno Therapeutics Breaks Above 200-Day Moving AverageBullish for SLNO - Nasdaq
Soleno Therapeutics (NASDAQ:SLNO) Trading 8.6% HigherHere's What Happened - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $74.83 Consensus PT from Brokerages - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential? - MSN
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
Analysts Predict How High Soleno Therapeutics Inc (SLNO) Will Go. - Stocks Register
Have Insiders Sold Soleno Therapeutics Shares Recently? - Simply Wall St
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
Trading (SLNO) With Integrated Risk Controls - Stock Traders Daily
Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven? - Yahoo Finance
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Soleno Therapeutics Inc Stock (SLNO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Yen Kristen | SEE REMARKS |
Jan 03 '25 |
Sale |
46.18 |
2,340 |
108,053 |
76,605 |
Mackaness James H | CHIEF FINANCIAL OFFICER |
Jan 02 '25 |
Sale |
45.41 |
4,083 |
185,406 |
115,089 |
Mackaness James H | CHIEF FINANCIAL OFFICER |
Jan 03 '25 |
Sale |
46.18 |
3,791 |
175,055 |
111,298 |
Hirano Patricia C | SEE REMARKS |
Jan 02 '25 |
Sale |
45.41 |
1,571 |
71,338 |
107,361 |
Hirano Patricia C | SEE REMARKS |
Jan 03 '25 |
Sale |
46.18 |
1,459 |
67,371 |
105,902 |
Anish Bhatnagar | CHIEF EXECUTIVE OFFICER |
Jan 02 '25 |
Sale |
45.41 |
10,937 |
496,640 |
708,616 |
Anish Bhatnagar | CHIEF EXECUTIVE OFFICER |
Jan 03 '25 |
Sale |
46.18 |
10,154 |
468,875 |
698,462 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):